Strides completes sale of Pivot Path stake for ₹1,000 million
Strides Pharma Science Limited has sold a majority stake in Pivot Path Private Limited to a consortium led by Ascent Capital for ₹1,000 million. Following the transaction, Pivot Path ceased to be a wholly owned subsidiary effective July 1, 2026, and is now classified as an associate company. The deal included a primary infusion of funds into Pivot Path, valuing the entity at approximately ₹2,300 million on a post-money basis.
*this image is generated using AI for illustrative purposes only.
Strides Pharma Science Limited has successfully completed the sale of a majority stake in its wholly owned subsidiary, Pivot Path Private Limited, to a consortium led by Ascent Capital and co-investor Vintage Classic. The transaction was executed for an aggregate consideration of approximately ₹1,000 million. Pursuant to the completion, Strides has received ₹750 million, with the balance consideration of ₹250 million payable on the first anniversary of the closing date. Consequent to this transaction, Pivot Path ceased to be a Wholly Owned Subsidiary of the company with effect from July 1, 2026, and shall henceforth be classified as an Associate Company.
The Board of Directors had approved the strategic investment at its meeting held on June 27, 2026. The deal, which also involved a primary infusion of approximately ₹500 million into Pivot Path by Ascent Capital, valued the entity at approximately ₹2,300 million on a post-money basis. The resultant capital structure sees Strides retain a 19.95% stake, while investors hold 65.05% and an ESOP Pool constitutes 15%.
Pivot Path originated within Arco Lab Private Limited, Strides' Global Capability Centre (GCC), and provides services in life sciences consulting, digital transformation, quality and compliance, and technology-enabled operational services. The business was carved out into Pivot Path pursuant to a Scheme of Arrangement approved by the National Company Law Tribunal (NCLT) in May 2026. For FY26, the carved-out business reported revenue of ₹1,447 million and EBITDA of ₹169 million.
Financial Contribution of Pivot Path
The following table details the contribution of Pivot Path to Strides' financials for FY 2025-26 on a post-demerger basis:
| Particulars: | Standalone Basis | Consolidated Basis |
|---|---|---|
| Turnover: | Nil | ₹1,447 million (Contributes 3% to Strides Turnover) |
| Networth: | ₹100 million (Contributes ~0.3% to Strides Networth) | ₹360 million (Contributes 1% to Strides Networth) |
Transaction Structure
The deal comprised the divestment of a majority stake by Strides and the infusion of primary capital into Pivot Path. The investors, Ascent Growth Trust and Vintage Classic Limited, do not belong to the promoter, promoter group, or group companies of Strides Pharma Science Limited. The transaction was based on an independent valuation conducted by a SEBI-registered merchant banker.
Historical Stock Returns for Strides Pharma Science
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.93% | -4.72% | -8.57% | +23.72% | +14.79% | +31.41% |
How does Strides Pharma plan to utilize the ₹750 million immediate cash inflow from the stake sale?
What impact will the deconsolidation of Pivot Path have on Strides' future consolidated revenue and EBITDA margins?
Will Strides maintain service level agreements with Pivot Path, or will the associate company be free to compete in the open market?
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
